Microbiome markers and therapies for autism spectrum disorders
The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neruotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘ Prevotella -like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus , Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella , is one of the three main classifiers for the human enterotypes, along with Bacteroides and Ruminococcus . These three core genera are among main contributors in the principle component analysis. ‘ Prevotella -like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes. The present disclosure provides for an understanding the association between gut microbiota, health, and disease states, and provides for potential diagnostic and therapeutic targets.
1. A method for treating autism spectrum disorder-gut related symptoms/complications in a subject comprising:
administering a probiotic comprising Prevotella , and/or Coprococcus , and/or Prevotellaceae, and/or Veillonellaceae to said subject, wherein said subject, prior to administration, has tested deficient for said Prevotella , and/or Coprococcus , and/or Prevotellaceae, and/or Veillonellaceae.
2. The method of claim 1 , further comprising, prior to administration:
subjecting a nucleic acid sample extracted from the gut of the subject to a genotyping assay that detects at least one of Prevotella, Coprococcus , Prevotellaceae, or Veillonellaceae bacteria; and
measuring a relative abundance of the at least one of Prevotella, Coprococcus , Prevotellaceae, or Veillonellaceae bacteria that is below a predetermined abundance to determine that the subject has tested deficient for Prevotella , and/or Coprococcus , and/or Prevotellaceae, and/or Veillonellaceae.
3. The method of claim 2 , wherein the predetermined abundance is a neurotypical amount.
4. The method of claim 2 , wherein the assay detects at least two of Prevotella, Coprococcus , Prevotellaceae, or Veillonellaceae.
5. The method of claim 2 , wherein the subjecting nucleic acid extracted from the subject to a genotyping assay comprises contacting the nucleic acid with at least one primer that specifically binds to 16S rRNA nucleic acid of at least one of Prevotella, Coprococcus , Prevotellaceae, or Veillonellaceae.
6. The method of claim 2 , further comprising comparing the detected relative abundance of the at least one of Prevotella, Coprococcus , Prevotellaceae, or Veillonellaceae bacteria to the predetermined abundance of the at least one of Prevotella, Coprococcus , Prevotellaceae, or Veillonellaceae bacteria.
7. The method of claim 2 , wherein the determining comprises obtaining nucleic acids from a stool sample and sequencing the nucleic acids with a deep sequencing technique.
8. The method of claim 7 , wherein the nucleic acids to be sequenced are bacterial 16S rRNA genes.
9. The method of claim 1 , further comprising, prior to administration:
subjecting protein extracted from a test sample of the subject to a protein assay that determines at least one protein indicative of at least one of Prevotella, Coprococcus , Prevotellaceae, or Veillonellaceae bacteria, the test sample including microbiota from a gut of the subject; and
determining a relative abundance of the at least one of Prevotella, Coprococcus , Prevotellaceae, or Veillonellaceae bacteria that is below a predetermined abundance to determine that the subject has tested deficient for Prevotella , and/or Coprococcus , and/or Prevotellaceae, and/or Veillonellaceae.
10. The method of claim 9 , wherein the protein assay includes at least one of 2-Dimensional Gel Electrophoresis, 2-Diminsional Difference Gel Electrophoresis (2D-DIGE), MALDI TOF-MS, (2D-) LC-ESI-MS/MS, AQUA, and iTRAQ.
11. The method of claim 9 , further comprising comparing the detected relative abundance of the at least one of Prevotella, Coprococcus , Prevotellaceae, or Veillonellaceae bacteria to the predetermined abundance of the at least one of Prevotella, Coprococcus , Prevotellaceae, or Veillonellaceae bacteria.
12. The method of claim 9 , wherein the determining comprises obtaining nucleic acids from a stool sample and sequencing the nucleic acids with a deep sequencing technique.
13. The method of claim 12 , wherein the nucleic acids to be sequenced are bacterial 16S rRNA genes.
14. The method of claim 9 , further comprising administering an agent to inhibit growth of at least one microorganism in the subject, wherein the microorganism is one having a higher relative abundance in the microbiome of autism spectrum disorder subjects compared with the microbiome of neurotypical subjects.